Integra LifeSciences (IART) Scheduled to Post Earnings on Monday

Integra LifeSciences (NASDAQ:IART) is set to announce its earnings results before the market opens on Monday, July 29th. Analysts expect the company to announce earnings of $0.62 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. The company had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. Integra LifeSciences’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 EPS. On average, analysts expect Integra LifeSciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $31.43 on Friday. The company has a fifty day moving average of $29.75 and a 200-day moving average of $33.84. The firm has a market capitalization of $2.48 billion, a P/E ratio of 62.86, a P/E/G ratio of 1.14 and a beta of 1.11. The company has a quick ratio of 3.35, a current ratio of 4.68 and a debt-to-equity ratio of 1.15. Integra LifeSciences has a twelve month low of $22.36 and a twelve month high of $46.75.

Analysts Set New Price Targets

A number of analysts have commented on IART shares. Bank of America decreased their price target on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research note on Tuesday, May 7th. Citigroup boosted their price target on shares of Integra LifeSciences from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, July 10th. JMP Securities decreased their price target on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 7th. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, Oppenheimer lowered shares of Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.86.

Insider Buying and Selling

In related news, Chairman Stuart Essig purchased 52,641 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.10% of the stock is owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.